Acura Rises After Pfizer-Partnered Painkiller Wins Approval

Acura Pharmaceuticals Inc., a maker of technology to deter drug abuse, rose the most in 11 weeks in Nasdaq trading after U.S. regulators approved its short-acting painkiller Oxecta.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.